Harvard Bioscience (HBIO) Misses Q4 EPS by 10c

Harvard Bioscience (NASDAQ: HBIO) reported Q4 EPS of ($0.06), $0.10 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $23.7 million versus the consensus estimate of $23.1 million.

For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.

You May Also Be Interested In

• EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
• Amylyx Pharmaceuticals (AMLX) 19K contracts trade
• UGI Corp. (UGI) call put ratio 8.5 calls to 1 put as share price up 11.5%